UnitedHealth Group (UNH) recently reported Q2 2026 results that topped revenue and adjusted EPS forecasts, alongside an improved adjusted operating margin supported by lower medical costs and higher full year earnings guidance.

UnitedHealth Group shares have eased in the past month with a 30 day share price return of down 5.48%, yet the year to date share price return of 20.57% and 1 year total shareholder return of 53.21% still point to positive momentum, even as long term 3 and 5 year total shareholder returns are more muted.

If you are thinking beyond a single insurer and want to see where healthcare meets data and automation, this is a good moment to scan 43 healthcare AI stocks

UnitedHealth Group appears to be a solid operator again after Q2, even though the stock has cooled over the past month. Does that recent share price pause mean you are paying up, or are you still paying a reasonable price for the quality on offer?

Most Popular Narrative: 2.7% Overvalued

The latest narrative fair value for UnitedHealth Group sits at $395, slightly under the last close at $405.59. That small gap reflects a view that the current price already bakes in most of the upside according to this analysis.

Our thesis centers on the fact that the market is discounting the massive value of Optum (Insight, Health, and Rx). While the insurance arm (UnitedHealthcare) is undergoing a painful but necessary "right-sizing", shedding ~1.4M members to prioritize margins, Optum continues to scale. By buying UNH at a 13x-15x Forward P/E, investors are essentially acquiring the world’s most powerful healthcare data ecosystem at a "legacy utility" multiple.

The narrative leans heavily on Optum as the quiet engine behind UnitedHealth Group, with future margins and cash generation tied to how this data driven platform scales and monetizes. Curious which growth, profitability and discount rate assumptions bridge the gap between today’s price and that $395 fair value band?

Result: Fair Value of $395 (OVERVALUED)

However, this UnitedHealth Group narrative could be knocked off course if Medicare Advantage regulation tightens further or if Optum’s cost and AI savings targets slip.

Another View on UnitedHealth Group’s Valuation

While the user narrative suggests UnitedHealth Group is 2.7% overvalued around $405.59, the SWS DCF model presents a very different picture. On that view, the stock trades at a 55.1% discount to an estimated future cash flow value of $903.47, which is a wide gap for any long term investor to ignore. Which perspective do you think better fits how you see this business?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out UnitedHealth Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of views on UnitedHealth Group is clear, so this is a good time to check the numbers yourself and decide how you feel about the balance of risks and rewards. To help you do that quickly, take a closer look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond UnitedHealth Group?

If you stop with UnitedHealth Group, you miss a wider set of opportunities. Use the Simply Wall Street Screener to quickly surface fresh ideas that match your style.

• Target potential upside in beaten down smaller companies by scanning 19 elite penny stocks with strong financials that still show solid financial foundations.
• Focus on value by checking 49 high quality undervalued stocks that combine quality fundamentals with prices that sit below estimated fair value.
• Prioritise resilience by reviewing 85 resilient stocks with low risk scores with balance sheets and risk scores that may better suit a steadier approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.